臨床外科62巻11号

2007年10月発行

特集 癌診療に役立つ最新データ2007-2008

Ⅹ．膵癌

膵癌の再発診療に関する最新のデータ

著者： 中森正二¹ 辻江正徳¹ 宮本敦史¹ 安井昌義¹ 池永雅一¹ 宮崎道彦¹ 平尾素宏¹ 藤谷和正¹ 三嶋秀行¹ 辻仲利政¹

所属機関： ¹国立病院機構大阪医療センター外科

ページ範囲：P.327 - P.335

文献概要

　要旨：膵癌切除例の再発率は高く，再発の診断・治療は重要であるが，いまだ標準的な診断・治療法は確立されていない．塩酸ゲムシタビンの出現以来，再発膵癌の治療の中心は塩酸ゲムシタビンであり，それを陵駕する治療薬は現れていない．再発膵癌の標準的診断法や治療のエビデンスを確立していくためには，実地臨床として施設ごとに異なった診断や治療を行って経験のみを蓄積していくよりも，多施設で共通したプロトコールに基づき大規模な臨床試験を行い，科学的根拠を作り上げていくことが必要であろう．

参考文献

1）膵癌登録報告2007．膵臓 22：e1-e427，2007

2）日本膵臓学会膵癌診療ガイドライン作成小委員会（編）：科学的根拠に基づく膵癌診療ガイドライン．金原出版，2006

3）大腸癌研究会（編）：大腸癌治療ガイドライン，医師用2005年版．金原出版，2005，p14，pp40-45

4）Kayahara M, Nagakawa T, Ueno K, et al：An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 72：2118-2123, 1993

5）Nakao A, Inoue S, Nomoto S, et al：Extended radical surgery for pancreatic carcinoma：Indications and oncological problems. Asian J Surg 20：192-197, 1997

6）Sperti C, Pasquali C, Piccoli A, et al：Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 21：195-200, 1997

7）上坂克彦，朴　成和，福富　晃，他：膵がん切除後の補助化学療法における塩酸ゲムシタビン療法とS-1療法の第Ⅲ相比較試験．膵臓 22：375，2007

8）Narimatsu H, Iwasaki H, Nakayama F, et al：Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 58：512-518, 1998

9）Montgomery RC, Hoffman JP, Riley LB, et al：Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 4：551-556, 1997

10）Ruf J, Lopez Hänninen E, Oettle H, et al：Detection of recurrent pancreatic cancer：Comparison of FDG-PET with CT/MRI. Pancreatology 5：266-272, 2005

11）Kalser MH, Ellenberg SS：Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120：899-903, 1985

12）Gastrointestinal Tumor Study Group：Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59：2006-2010, 1987

13）Klinkenbijl JH, Jeekel J, Sahmoud T, et al：Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region：Phase Ⅲ trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230：776-782, 1999

14）Neoptolemos JP, Stocken DD, Friess H, et al：European Study Group for Pancreatic Cancer：A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350：1200-1210, 2004

15）Bakkevold KE, Arnesjo B, Dahl O, et al：Adjuvant combination chemotherapy（AMF）following radical resection of carcinoma of the pancreas and papilla of Vater―results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29A：698-703, 1993

16）Burris HA 3rd, Moore MJ, Andersen J, et al：Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer：A randomized trial. J Clin Oncol 15：2403-2413, 1997

17）Oettle H, Post S, Neuhaus P, et al：Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer：A randomized controlled trial. JAMA 297：267-277, 2007

18）小菅智男：「膵癌診療ガイドライン」をめぐって―外科療法―補助化学療法．膵臓 22：291，2007

19）NCCN Clinical Practice Guidelines in Oncology―V. 1. 2007：Pancreatic adenocarcinoma（http://www.nccn.org/professionals/physician_gls/）

20）Tempero M, Plunkett W, Van Haperen VR, et al：Randomized phase Ⅱ comparison of dose-intense gemcitabine：Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Onco 21：3402-3408, 2003

21）Berlin JD, Catalano P, Thomas JP, et al：Phase Ⅲ study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma：Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20：3270-3275, 2002

22）Bramhall SR, Schulz J, Nemunaitis J, et al：A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87：161-167, 2002

23）Rocha Lima CM, Green MR, Rotche R, et al：Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22：3776-3783, 2004

24）O'Reilly EM, Abou-Alfa GK, Letournrau R, et al：A randomized phase Ⅲ trial of DX-8951f（Exatecan mesylate；DX）and gemcitabine（GEM）vs. gemcitabine alone in advanced pancreatic cancer（APC）. J Clin Oncol 22：315, 2004（suppl 14, abstract 4006）

25）Van Cutsem E, van de Velde H, Karasek P, et al：Phase Ⅲ trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22：1430-1438, 2004

26）Oettle H, Richards D, Ramanathan RK, et al：A phase Ⅲ trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16：1639-1645, 2005

27）Di Costanzo F, Carlini P, Doni L, et al：Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer：A randomised phaseⅡ trial of the Italian oncology group for clinical research（GOIRC）. Br J Cancer 93：185-189, 2005

28）Riess H, Helm A, Niedergethmann M, et al：A randomized, prosprctive, multicenter, phase Ⅲ trial of gemcitabine, 5-fluorouracil（5-FU）, folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 23：1032, 2005（suppl 16, abstract 4009）

29）Louvet C, Labianca R, Hammel P, et al：Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer：Rresults of a GERCOR and GISCAD phase Ⅲ trial. J Clin Oncol 23：3509-3516, 2005

30）Heinemann V, Quietzsch D, Gieseler F, et al：Randomized phase Ⅲ trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24：3946-3952, 2006

31）Poplin E, Levy DE, Berlin J, et al：Phase Ⅲ trial of gemcitabine（30-minnute infusion）versus gemcitabine（fixed-dose-rate infusion［FDR］versus gemcitabine＋oxaliplatin（GEMOX）in patients with advanced pancreatic cancer（E6201）. J Clin Oncol 24：18S, 2006（abstract 4004）

32）Herrmann R, Bodoky G, Ruhstaller T, et al：Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer：A randomized, multicenter, phase Ⅲ trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25：2212-2217, 2007

33）Moore MJ, Goldstein D, Hamm J, et al：Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer：A phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25：1960-1966, 2007

34）Ueno H, Okusaka T, Ikeda M, et al：An early phaseⅡ study of S-1 in patients with metastatic pancreatic cancer. Oncology 68：171-178, 2005

35）Nakamura K, Yamaguchi T, Ishihara T, et al：PhaseⅡ trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94：1575-1579, 2006

36）Okusaka T, Funakoshi A, Furuse J, et al：A late phaseⅡ study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2007 May 23（Epub ahead of print）

37）Wilkowski R, Thoma M, Bruns C, et al：Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP 7：34-40, 2006

38）Kleeff J, Reiser C, Hinz U, et al：Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 245：566-572, 2007

39）大腸癌研究会（編）：大腸癌治療ガイドライン，医師用2005年版．金原出版，2005，pp11，pp24-26